Copyright Reports & Markets. All rights reserved.

Global T Cell Specific Surface Glycoprotein CD28 Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 T Cell Specific Surface Glycoprotein CD28 Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global T Cell Specific Surface Glycoprotein CD28 Market Size Growth Rate by Product
      • 1.4.2 FPT-155
      • 1.4.3 FR-104
      • 1.4.4 Lulizumab Pegol
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global T Cell Specific Surface Glycoprotein CD28 Market Size Growth Rate by End User
      • 1.5.2 Plaque Psoriasis
      • 1.5.3 Solid Tumor
      • 1.5.4 Acute Renal Failure(ARF)
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global T Cell Specific Surface Glycoprotein CD28 Market Size
      • 2.1.1 Global T Cell Specific Surface Glycoprotein CD28 Revenue 2014-2025
      • 2.1.2 Global T Cell Specific Surface Glycoprotein CD28 Sales 2014-2025
    • 2.2 T Cell Specific Surface Glycoprotein CD28 Growth Rate by Regions
      • 2.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Regions
      • 2.2.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 T Cell Specific Surface Glycoprotein CD28 Sales by Manufacturers
      • 3.1.1 T Cell Specific Surface Glycoprotein CD28 Sales by Manufacturers
      • 3.1.2 T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Manufacturers
      • 3.1.3 Global T Cell Specific Surface Glycoprotein CD28 Market Concentration Ratio (CR5 and HHI)
    • 3.2 T Cell Specific Surface Glycoprotein CD28 Revenue by Manufacturers
      • 3.2.1 T Cell Specific Surface Glycoprotein CD28 Revenue by Manufacturers (2014-2019)
      • 3.2.2 T Cell Specific Surface Glycoprotein CD28 Revenue Share by Manufacturers (2014-2019)
    • 3.3 T Cell Specific Surface Glycoprotein CD28 Price by Manufacturers
    • 3.4 T Cell Specific Surface Glycoprotein CD28 Manufacturing Base Distribution, Product Types
      • 3.4.1 T Cell Specific Surface Glycoprotein CD28 Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers T Cell Specific Surface Glycoprotein CD28 Product Type
      • 3.4.3 Date of International Manufacturers Enter into T Cell Specific Surface Glycoprotein CD28 Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Product
    • 4.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Product
    • 4.3 T Cell Specific Surface Glycoprotein CD28 Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global T Cell Specific Surface Glycoprotein CD28 Breakdown Data by End User

    6 North America

    • 6.1 North America T Cell Specific Surface Glycoprotein CD28 by Countries
      • 6.1.1 North America T Cell Specific Surface Glycoprotein CD28 Sales by Countries
      • 6.1.2 North America T Cell Specific Surface Glycoprotein CD28 Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America T Cell Specific Surface Glycoprotein CD28 by Product
    • 6.3 North America T Cell Specific Surface Glycoprotein CD28 by End User

    7 Europe

    • 7.1 Europe T Cell Specific Surface Glycoprotein CD28 by Countries
      • 7.1.1 Europe T Cell Specific Surface Glycoprotein CD28 Sales by Countries
      • 7.1.2 Europe T Cell Specific Surface Glycoprotein CD28 Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe T Cell Specific Surface Glycoprotein CD28 by Product
    • 7.3 Europe T Cell Specific Surface Glycoprotein CD28 by End User

    8 Asia Pacific

    • 8.1 Asia Pacific T Cell Specific Surface Glycoprotein CD28 by Countries
      • 8.1.1 Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales by Countries
      • 8.1.2 Asia Pacific T Cell Specific Surface Glycoprotein CD28 Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific T Cell Specific Surface Glycoprotein CD28 by Product
    • 8.3 Asia Pacific T Cell Specific Surface Glycoprotein CD28 by End User

    9 Central & South America

    • 9.1 Central & South America T Cell Specific Surface Glycoprotein CD28 by Countries
      • 9.1.1 Central & South America T Cell Specific Surface Glycoprotein CD28 Sales by Countries
      • 9.1.2 Central & South America T Cell Specific Surface Glycoprotein CD28 Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America T Cell Specific Surface Glycoprotein CD28 by Product
    • 9.3 Central & South America T Cell Specific Surface Glycoprotein CD28 by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa T Cell Specific Surface Glycoprotein CD28 by Countries
      • 10.1.1 Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales by Countries
      • 10.1.2 Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa T Cell Specific Surface Glycoprotein CD28 by Product
    • 10.3 Middle East and Africa T Cell Specific Surface Glycoprotein CD28 by End User

    11 Company Profiles

    • 11.1 Atox Bio Ltd
      • 11.1.1 Atox Bio Ltd Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Products Offered
      • 11.1.5 Atox Bio Ltd Recent Development
    • 11.2 Bristol-Myers Squibb Co
      • 11.2.1 Bristol-Myers Squibb Co Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Products Offered
      • 11.2.5 Bristol-Myers Squibb Co Recent Development
    • 11.3 Five Prime Therapeutics Inc
      • 11.3.1 Five Prime Therapeutics Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Products Offered
      • 11.3.5 Five Prime Therapeutics Inc Recent Development
    • 11.4 Johnson & Johnson
      • 11.4.1 Johnson & Johnson Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Products Offered
      • 11.4.5 Johnson & Johnson Recent Development
    • 11.5 TheraMAB LLC
      • 11.5.1 TheraMAB LLC Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Products Offered
      • 11.5.5 TheraMAB LLC Recent Development

    12 Future Forecast

    • 12.1 T Cell Specific Surface Glycoprotein CD28 Market Forecast by Regions
      • 12.1.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Forecast by Regions 2019-2025
      • 12.1.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue Forecast by Regions 2019-2025
    • 12.2 T Cell Specific Surface Glycoprotein CD28 Market Forecast by Product
      • 12.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Forecast by Product 2019-2025
      • 12.2.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue Forecast by Product 2019-2025
    • 12.3 T Cell Specific Surface Glycoprotein CD28 Market Forecast by End User
    • 12.4 North America T Cell Specific Surface Glycoprotein CD28 Forecast
    • 12.5 Europe T Cell Specific Surface Glycoprotein CD28 Forecast
    • 12.6 Asia Pacific T Cell Specific Surface Glycoprotein CD28 Forecast
    • 12.7 Central & South America T Cell Specific Surface Glycoprotein CD28 Forecast
    • 12.8 Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 T Cell Specific Surface Glycoprotein CD28 Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global T Cell Specific Surface Glycoprotein CD28 market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the T Cell Specific Surface Glycoprotein CD28 market based on company, product type, end user and key regions.

      This report studies the global market size of T Cell Specific Surface Glycoprotein CD28 in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of T Cell Specific Surface Glycoprotein CD28 in these regions.
      This research report categorizes the global T Cell Specific Surface Glycoprotein CD28 market by top players/brands, region, type and end user. This report also studies the global T Cell Specific Surface Glycoprotein CD28 market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Atox Bio Ltd
      Bristol-Myers Squibb Co
      Five Prime Therapeutics Inc
      Johnson & Johnson
      TheraMAB LLC

      Market size by Product
      FPT-155
      FR-104
      Lulizumab Pegol
      Others
      Market size by End User
      Plaque Psoriasis
      Solid Tumor
      Acute Renal Failure(ARF)
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global T Cell Specific Surface Glycoprotein CD28 market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of T Cell Specific Surface Glycoprotein CD28 market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global T Cell Specific Surface Glycoprotein CD28 companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of T Cell Specific Surface Glycoprotein CD28 submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of T Cell Specific Surface Glycoprotein CD28 are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of T Cell Specific Surface Glycoprotein CD28 market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now